CVS Health (1CVS) Stock Overview
Provides health solutions in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
Last Earnings Call
Q2 2026 · 5 Aug 2026CVS Health reported strong Q2 2026 results on August 5, 2026, with total revenues of $106.1 billion and adjusted earnings per share (EPS) of $2.58. Both metrics comfortably beat analyst consensus estimates of approximately $100.03 billion in revenue and $1.83–$1.86 in EPS.
Key financial drivers included significant margin recovery within the Health Care Benefits segment, fueled by disciplined medical cost management in its government business, and steady growth across all operating segments. Consequently, management raised its full-year 2026 adjusted EPS guidance to a range of $7.90–$8.10, up from the prior $7.30–$7.50, and increased its operating cash flow outlook to at least $11.5 billion. While providing preliminary 2027 commentary, management signaled a potential $8.44 adjusted EPS floor, noting anticipated membership headwinds in its Caremark PBM business and ongoing pressure in 340B programs.
Market Reaction
Despite initial pre-market gains following the earnings beat and raised guidance, CVS stock fell by approximately 6.5% during regular trading hours on August 5, 2026. Analysts attributed the reversal to management's cautious commentary regarding 2027 headwinds, specifically membership declines in the Caremark segment and 340B-related pressures.
1CVS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
CVS Health Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$82.70 |
| 52 Week High | US$95.80 |
| 52 Week Low | US$59.57 |
| Beta | 0.60 |
| 1 Month Change | -9.78% |
| 3 Month Change | 5.73% |
| 1 Year Change | 49.28% |
| 3 Year Change | 22.16% |
| 5 Year Change | 14.86% |
| Change since IPO | 21.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1CVS | IT Healthcare | IT Market | |
|---|---|---|---|
| 7D | -9.6% | 1.3% | 2.6% |
| 1Y | 49.3% | 2.7% | 24.7% |
Return vs Industry: 1CVS exceeded the Italian Healthcare industry which returned 2.7% over the past year.
Return vs Market: 1CVS exceeded the Italian Market which returned 24.7% over the past year.
Price Volatility
| 1CVS volatility | |
|---|---|
| 1CVS Average Weekly Movement | 3.9% |
| Healthcare Industry Average Movement | 4.8% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in IT Market | 8.0% |
| 10% least volatile stocks in IT Market | 2.8% |
Stable Share Price: 1CVS has not had significant price volatility in the past 3 months compared to the Italian market.
Volatility Over Time: 1CVS's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1963 | 259,500 | J. Joyner | www.cvshealth.com |
CVS Health Corporation provides health solutions in the United States. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental, and behavioral health plans; medical management capabilities; Medicare Advantage and Medicare Supplement plans; prescription drug plans (PDPs); and Medicaid health care management services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates.
CVS Health Corporation Fundamentals Summary
| 1CVS fundamental statistics | |
|---|---|
| Market cap | €105.85b |
| Earnings (TTM) | €4.23b |
| Revenue (TTM) | €356.86b |
Is 1CVS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1CVS income statement (TTM) | |
|---|---|
| Revenue | US$412.65b |
| Cost of Revenue | US$356.34b |
| Gross Profit | US$56.31b |
| Other Expenses | US$51.42b |
| Earnings | US$4.89b |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.82 |
| Gross Margin | 13.64% |
| Net Profit Margin | 1.19% |
| Debt/Equity Ratio | 76.9% |
How did 1CVS perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/09 19:35 |
| End of Day Share Price | 2026/08/07 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CVS Health Corporation is covered by 49 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Harshit Gupta | Accountability Research Corporation |
| Christopher Graja | Argus Research Company |
| Hua Ha | Baird |